Boncresa PFS Q Code: Q5171

Drug & Product Overview

HCPCS Descriptor Injection, denosumab-mobz (boncresa), biosimilar, 1 mg

HCPCS Added Date July 1, 2026

Manufacturer Amneal Biosciences

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Form Injection, Solution

About Boncresa PFS

Boncresa PFS is a medication aligned to the HCPCS Q Code: Q5171 for billing, pricing, and reimbursement purposes in the United States. This Osteoporosis medication is administered via the subcutaneous route and manufactured by Amneal Biosciences.

Manufacturers, reach out to us to add more information.

NDC Code Information

1 NDC package is crosswalked to Q5171. Package detail is available to logged-in subscribers.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
•••••-••••-•• Log in to view	Boncresa PFS

Login to view 1 NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Denosumab Biosimilar Information:

Boncresa PFS Approval Date: December 19, 2025

Product Name	HCPCS Code	Active Ingredient	BLA Type
Prolia	J0897	Denosumab	351(a) Originator Product
Jubbonti and Wyost	Q5136	Denosumab	351(k) Interchangeable
Ospomyv and Xbryk	Q5159	Denosumab	351(k) Interchangeable
Stoboclo and Osenvelt	Q5157	Denosumab	351(k) Interchangeable
Bomyntra and Conexxence	Q5158	Denosumab	351(k) Interchangeable
Bildyos and Bilprevda	Q5162	Denosumab	351(k) Interchangeable
Aukelso and Bosaya	Q5161	Denosumab	351(k) Interchangeable
Enoby and Xtrenbo	Q5167	Denosumab	351(k) Interchangeable
Osvyrti and Jubereq	Q5166	Denosumab	351(k) Interchangeable
Oziltus	Q5165	Denosumab	351(k) Interchangeable
Boncresa	Q5171	Denosumab	351(k) Interchangeable
Ponlimsi	Q5173	Denosumab	351(k) Interchangeable

Boncresa PFS CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Boncresa PFS Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer Glucocorticoid-induced osteoporosis Osteoporosis at high risk for fracture

Drug Class

RANK Ligand Blocking Activity [MoA]RANK Ligand Inhibitor [EPC]

Frequently Asked Questions

Is there an available Boncresa PFS billing and coding guide?

A manufacturer-published billing and coding guide for BONCRESA PFS was not found.

Are there any available Boncresa patient assistance programs?

No manufacturer-published BONCRESA PFS patient assistance link was found.

Where can I find Boncresa Pfs prescribing information?

BONCRESA PFS prescribing information can be found at the link below: Visit Here →

Where can I find Boncresa Pfs side effect information?

No BONCRESA PFS side effect information link was found.

Does billing BONCRESA PFS require JZ/JW wastage modifiers?

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.